Pulsatile Erlotinib in EGFR-Positive Non-Small Cell Lung Cancer Patients with Leptomeningeal and Brain Metastases: Review of the Literature

Patients with epidermal growth factor receptor (EGFR) positive non-small cell lung cancer (NSCLC) show improved response rates when treated with tyrosine kinase inhibitors (TKIs) such as erlotinib. However, standard daily dosing of erlotinib often does not reach therapeutic concentrations within the cerebrospinal fluid (CSF), resulting in progression of central nervous system (CNS) disease. Intermittent, high dose administration of erlotinib reaches therapeutic concentrations within the CSF and is well-tolerated in patients.

from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2lq3g6Q
via IFTTT